12 min
A New Vaccine Frontrunner Prognosis: Losing it
-
- Science
As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.
As competitors publicly entered the race to produce a vaccine, drug giant Merck stayed quiet about its development plans. Now, the company has revealed it’s working on two vaccines and a treatment pill -- emerging as a frontrunner in the development contest. Although the company has refused to give firm timelines for its research, it has pledged to make its vaccines and pill available globally, if they're successful. Riley Griffin talked with Merck Chief Executive Kenneth C. Frazier about the company's plans.
See omnystudio.com/listener for privacy information.
12 min
Top Podcasts In Science